Locksmith Bio
Drugging the undruggable.
Locksmith Bio uses physics-based AI to map intrinsically disordered protein regions, revealing novel drug targets. Biopharma researchers leverage these insights to design therapeutics against proteins previously deemed undruggable, accelerating early-stage drug discovery efforts.
Founders
Ajitesh Lunge
CEO
Ajitesh is a clinician-scientist and holds a PhD in Translational Medicine from India’s top-ranked university, where he discovered a novel drug for tuberculosis.
Yashas Devasurmutt
CTO
Yash is a bioengineer who previously led a project studying tardigrades in the Himalaya, backed by Stanford University and the Government of India. He also led R&D at India’s #1 research institute.